Life Biosciences

Life Biosciences Co., Ltd. ("Life Biosciences") was established in August 2021 and is committed to building an internationally leading technology service platform for model animals and innovative drug and device R&D. Based on high-standard experimental animal resources, Life Biosciences has developed high-quality, full-category animal models and research service capabilities. The company has established multiple experimental animal resource bases across China, providing high-quality experimental animals such as cynomolgus monkeys, rhesus monkeys, marmosets, and beagle dogs. Life Biosciences owns several SPF-grade animal facilities, housing suitable for medium and large-sized experimental animals, well-equipped laboratories, and an excellent team specializing in animal model development and experimental techniques in cities like Beijing, Shenzhen, and Guangzhou. It offers more than 100 models related to the central nervous system and brain science, oncology, cardiovascular diseases, metabolic disorders, autoimmune conditions, orthopedics, etc., placing it at the forefront in China. Currently, the company provides clients with a comprehensive range of services for innovative drug R&D experiments, including specialized models, pharmacology and efficacy studies, pharmacokinetics, and early toxicity assessments, as well as medical device effectiveness and safety evaluation experiments. Life Biosciences is deeply involved in the R&D and testing of cutting-edge medical devices in CNS and brain science, CGT field drugs, brain-computer interfaces, and neuromodulation in China.